ArticleAntimicrobial agents and chemotherapy2019
Molecular Analysis of Linezolid-Resistant Clinical Isolates of
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Ribosomal protection as a linezolid resistance mechanism inAntimicrobial agents and chemotherapy · 2026Article
- A Frameshift Mutation in the MethyltransferaseComputational and structural biotechnology journal · 2026Article
- Ribosomal protection as a linezolid resistance mechanism inbioRxiv : the preprint server for biology · 2025Article
- Mutations in the transcriptional regulator MAB_2885 confer tedizolid and linezolid resistance through the MmpS-MmpL efflux pump MAB_2302-MAB_2303 in Mycobacterium abscessus.PLoS pathogens · 2025Article
- Dual Mutations inInternational journal of molecular sciences · 2025Article
- GrcC1 mediates low-level resistance to multiple drugs inMicrobiology spectrum · 2025Article
- Population genetic analysis of clinicalFrontiers in cellular and infection microbiology · 2024Article
- Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease.Annals of clinical microbiology and antimicrobials · 2023Article
- Characterization ofMicrobiology spectrum · 2023Article
- Mechanisms of Linezolid Resistance in Mycobacteria.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Epidemiology of Nontuberculous Mycobacteria in Nanjing andInfection and drug resistance · 2023Article
- Article
- A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus ActivityAntimicrobial agents and chemotherapy · 2021Article
- Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance ofInfection and drug resistance · 2020Article
- Radezolid Is More Effective Than Linezolid Against Planktonic Cells and InhibitsFrontiers in microbiology · 2020Article
- Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical,Infection and drug resistance · 2020Article
- Review
- The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2019Article
- Hospital outbreak caused by linezolid resistantAntimicrobial resistance and infection control · 2019Article
- Clinical Efficacy and Adverse Effects of Antibiotics Used to TreatFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 194
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.